Clinical significance and tolerability

John Bazar compares the three‑month OS gain to bevacizumab and reviews pemetrexed tolerability and dose intensity.

Play episode from 06:58

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!